Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02740972 · ClinicalTrials.gov registry record · Phase 2
Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase 2 study, sponsored by NS Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02740972 is a Phase 2 study that has completed, run by NS Pharma. The registered enrollment target is 16 participants.
The verdict
NCT02740972, a Phase 2 study, has completed, sponsored by NS Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the safety of a high (80mg/kg) and low (40mg/kg) dose of NS-065/NCNP-01 delivered as an intravenous infusion in patients with Duchenne Muscular Dystrophy (DMD) amendable to exon 53 skipping. Additional objectives include tolerability, muscle function and strength, pharmacokinetics and pharmacodynamics.
Interventions
- DRUG Placebo
- DRUG NS-065/NCNP-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02740972
The ClinicalTrials.gov registry entry for NCT02740972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NS Pharma, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02740972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02740972 about?
NCT02740972 is a clinical study titled "Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)". The main objective of this study is to evaluate the safety of a high (80mg/kg) and low (40mg/kg) dose of NS-065/NCNP-01 delivered as an intravenous infusion in patients with Duchenne Muscular Dystrophy (DMD) amendable to exon 53 skipping. Additional objectives include tolerability, muscle function a...
What is the current status of trial NCT02740972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2016-12. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02740972?
The interventions under investigation include: Placebo (DRUG), NS-065/NCNP-01 (DRUG).
Who is sponsoring clinical trial NCT02740972?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.